🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. EFGARTIGIMOD ALFA, JNJ-80202135

    Janssen-Cilag International N.V.

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  2. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  3. ELECTROLYTES , VIALEBEX 200 g/L, solution pour perfusion

    Pari Pharma GmbH

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

    phase 3 small molecule active

    1 trial

  4. ELOXATINE 5 mg/ml, solution à diluer pour perfusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer and rectal with liver metastasis

    phase 3 small molecule active

    1 trial

  5. EMPAGLIFLOZIN, BI 690517, Placebo matching vicadrostat

    Boehringer Ingelheim

    Heart failure

    phase 3 small molecule active

    1 trial

  6. EMPAGLIFLOZIN, Placebo matching BI 690517, BI 690517

    Boehringer Ingelheim

    Heart failure (HF)

    phase 3 small molecule active

    1 trial

  7. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  8. ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  9. ESTREVA 0,1 %, gel, ANDROGEL 16,2 mg/g, gel, PROVAMES 1 mg, comprimé pelliculé

    Pari Pharma GmbH

    gender dysphoria

    phase 3 small molecule active

    1 trial

  10. ETOPOSIDE, ATEZOLIZUMAB, PF-08634404, CARBOPLATIN

    Pfizer Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  12. ETOPOSIDE, PACLITAXEL, IFOSFAMIDE, CISPLATIN, CARBOPLATIN

    Ningbo Cancer Hospital

    Progressive or recurrent germ cell tumor (measurable or non-measurable)

    phase 3 small molecule active

    1 trial

  13. EVENITY 105 mg solution for injection in pre-filled syringe, EVENITY 105 mg solution for injection in pre-filled syringe, EVENITY 105 mg solution for injection in pre-filled pen, EVENITY 105 mg solution for injection in pre-filled pen

    Amgen

    Osteogenesis Imperfecta

    phase 3 small molecule active

    1 trial

  14. Ebglyss 250 mg solution for injection in pre-filled syringe, Placebo, Ebglyss 250 mg solution for injection in pre-filled pen

    Almirall, S.A.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  15. Efgartigimod PH20 SC

    argenx

    Primary Sjogrens Disease

    phase 3 mab active

    1 trial

  16. Efgartigimod, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  17. Efluelda Injektionssuspension in einer Fertigspritze Trivalenter Influenza-Spaltimpfstoff (inaktiviert), 60 Mikrogramm HA/Stamm, Influvac, suspensie voor injectie 0,5 ml (influenza vaccin, oppervlakte antigeen, geïnactiveerd)., Trivalent Influenza Vaccine - High Dose (TIV-HD)

    Abbott Laboratories

    Influenza immunisation

    phase 3 small molecule active

    1 trial

  18. Elective nodal irradiation (ENI)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma

    phase 3 other active

    1 trial

  19. Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat, Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat

    Genzyme Europe B.V.

    Gaucher's disease type I; Gaucher's disease type III

    phase 3 small molecule active

    1 trial

  20. Empagliflozin

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  21. Empagliflozin

    Boehringer Ingelheim

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  22. Empagliflozin

    Boehringer Ingelheim

    Heart Failure

    phase 3 small molecule completed

    1 trial

  23. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  24. Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe

    Mabxience Research SL

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources